Trials, tribulations and transparency: the EU pharma regulatory scene in 2013
This article was originally published in SRA
Executive Summary
As EU regulatory developments go, 2012 will be a hard act to follow. The year saw a host of high-profile events, notably the adoption of the draft regulation on clinical trials, new legislation on transparency in drug pricing and reimbursement and yet another round of laws on pharmacovigilance.